Printer Friendly
The Free Library
14,735,091 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Atazanavir (Reyataz): new recommendations if combined with tenofovir (Viread)--and warning on Viagra, Cialis, and Levitra.


On March 19, 2004 the FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 notified the public of new prescribing information and precautions precautions Infectious disease The constellation of activities intended to minimize exposure to an infectious agent; precautions imply that the isolation of an infected Pt is optional, but not mandatory.  for atazanavir (brand name Reyataz), if taken in combination with tenofovir tenofovir /te·no·fo·vir/ (te-no´fo-vir?) an antiretroviral agent that inhibits reverse transcriptase; used as t. disoproxil fumarate in the treatment of HIV-1 (human immunodeficiency virus-1) infection.  (Viread)--and warned of risks with Viagra or similar drugs.

If atazanavir is taken with tenofovir, the blood level of atazanavir is decreased. Therefore it is now recommended that a small dose of ritonavir ritonavir /ri·to·na·vir/ (ri-to´nah-vir) an HIV protease inhibitor used in treatment of HIV infection and AIDS.

ri·ton·a·vir
n.
 be taken in addition, to raise the blood level of atazanavir to compensate. All three drugs are taken together once per day, with food.

Also, Reyataz increases the blood level of Viread, which could increase its side effects Side effects

Effects of a proposed project on other parts of the firm.
. As a precaution, patients combining the drugs should be monitored for tenofovir side effects.

The new Patient Information flyer also warns that if atazanavir is combined with Viagra, Cialis, or Levitra, it could increase the risk of serious side effects of those drugs. Patients are advised not to combine atazanavir with any of these drugs unless their doctor tells them it is OK.

For more information see the new prescribing information for atazanavir, which will be posted at http://www.reyataz.com (we did not find it on the site on April 14). Also see the Patient Information flyer, which may be posted at the end of the prescribing information.
COPYRIGHT 2004 John S. James
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:AIDS Treatment News
Article Type:Brief Article
Geographic Code:1USA
Date:Mar 26, 2004
Words:208
Previous Article:Atherosclerosis risk increased with HIV; treatment effects unclear.
Next Article:Abacavir hypersensitivity reaction predicted by genetic test.(Brief Article)
Topics:



Related Articles
Tenofovir approved: Broad indication.(Brief Article)
Tenofovir (Viread[R]) access for poor countries.
New protease inhibitor atazanavir (Reyataz[TM]) approved.(Reyataz)
Failure of combination abacavir + tenofovir + lamivudine (3TC).(Brief Article)
HIV drugs approved as of August 2003.
Warning against Tenofovir+ddI+3TC, and "Triple Nuke" combinations.(Brief Article)
Revised U.S. Adult and Adolescent Antiretroviral Treatment Guidelines; also Revised Pediatric Guidelines.
FDA approves two combination pills, Epzicom and Truvada; comment on commercial race to once-a-day nucleosides.
New fixed-dose once-a-day starting regimens: interview with Cal Cohen, M.D.(Interview)
Warning: do not combine Reyataz and Prilosec.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles